JP2020530981A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530981A5
JP2020530981A5 JP2019572710A JP2019572710A JP2020530981A5 JP 2020530981 A5 JP2020530981 A5 JP 2020530981A5 JP 2019572710 A JP2019572710 A JP 2019572710A JP 2019572710 A JP2019572710 A JP 2019572710A JP 2020530981 A5 JP2020530981 A5 JP 2020530981A5
Authority
JP
Japan
Prior art keywords
antisense oligonucleotide
exon
cell
target region
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019572710A
Other languages
English (en)
Japanese (ja)
Other versions
JP7284718B2 (ja
JP2020530981A (ja
Filing date
Publication date
Priority claimed from SG10201705285SA external-priority patent/SG10201705285SA/en
Application filed filed Critical
Publication of JP2020530981A publication Critical patent/JP2020530981A/ja
Publication of JP2020530981A5 publication Critical patent/JP2020530981A5/ja
Application granted granted Critical
Publication of JP7284718B2 publication Critical patent/JP7284718B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019572710A 2017-06-27 2018-06-27 T細胞の機能を調節するためのアンチセンスオリゴヌクレオチド Active JP7284718B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201705285S 2017-06-27
SG10201705285SA SG10201705285SA (en) 2017-06-27 2017-06-27 Antisense oligonucleotides
PCT/SG2018/050313 WO2019004939A1 (en) 2017-06-27 2018-06-27 ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A LYMPHOCYTE T

Publications (3)

Publication Number Publication Date
JP2020530981A JP2020530981A (ja) 2020-11-05
JP2020530981A5 true JP2020530981A5 (cg-RX-API-DMAC7.html) 2021-07-29
JP7284718B2 JP7284718B2 (ja) 2023-05-31

Family

ID=64742433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572710A Active JP7284718B2 (ja) 2017-06-27 2018-06-27 T細胞の機能を調節するためのアンチセンスオリゴヌクレオチド

Country Status (9)

Country Link
US (1) US12188016B2 (cg-RX-API-DMAC7.html)
EP (1) EP3645724A4 (cg-RX-API-DMAC7.html)
JP (1) JP7284718B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200035937A (cg-RX-API-DMAC7.html)
CN (1) CN111630167B (cg-RX-API-DMAC7.html)
AU (1) AU2018291556B2 (cg-RX-API-DMAC7.html)
CA (1) CA3066035A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201705285SA (cg-RX-API-DMAC7.html)
WO (1) WO2019004939A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
US11576932B2 (en) * 2016-03-31 2023-02-14 Lion Tcr Pte. Ltd. Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR)
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
CN112840026B (zh) * 2018-10-18 2025-01-14 施能康公司 抑制tigit基因表达的组合物和方法
US20220177894A1 (en) * 2019-04-02 2022-06-09 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for immunotherapy
CN109988842B (zh) * 2019-04-19 2022-12-06 上海吉玛制药技术有限公司 一种寡核苷酸标记探针原位检测pdl1的试剂组与应用
EP3959313A4 (en) * 2019-04-26 2023-09-27 Stoke Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING OF ALTERNATIVE INTRONS
CN110157705B (zh) * 2019-05-16 2021-06-18 苏州安天圣施医药科技有限公司 在pdcd1基因表达的剪接水平抑制pd-1信号的反义寡核苷酸及其筛选方法与应用
US20220380774A1 (en) * 2019-05-20 2022-12-01 Olix Pharmaceuticals, Inc. Asymmetric sirna inhibiting expression of pd-1
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
EP4076476A4 (en) * 2019-12-17 2023-11-22 The General Hospital Corporation MODIFIED IMMUNE CELLS WITH REDUCED TOXICITY AND THEIR USES
WO2021173812A1 (en) * 2020-02-28 2021-09-02 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
KR20230016623A (ko) * 2020-04-30 2023-02-02 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 Pd-1-특이적 안티센스 올리고뉴클레오티드 및 요법에서의 이의 용도
EP4211241A1 (en) * 2020-09-10 2023-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of splice switching oligonucleotides for exon skipping-mediated knockdown of nf-kb components in b cells
WO2022084389A1 (en) * 2020-10-20 2022-04-28 Immunoa Pte. Ltd. Modified immune cells
CN116670282A (zh) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 靶向xbp1的寡核苷酸
CN115216474B (zh) * 2021-04-15 2025-09-30 武汉大学 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用
EP4074835A1 (en) * 2021-04-15 2022-10-19 Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg H-1 pv expressing rnai effectors
WO2023073709A1 (en) * 2021-10-27 2023-05-04 Hadasit Medical Research Services & Development Ltd. Nucleic acid agents modulating pd-1 isoforms
CN118956872A (zh) * 2024-08-16 2024-11-15 首都医科大学附属北京朝阳医院 IFN-γ mRNA的反义寡核苷酸及其应用和药用组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566132B1 (en) 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
AU2006311586A1 (en) * 2005-11-08 2007-05-18 Avi Biopharma, Inc. Immunosuppression compound and treatment method
LT2735568T (lt) 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
WO2011120101A1 (en) 2010-04-01 2011-10-06 The University Of Queensland Small rna molecules and methods of use
WO2013135830A1 (en) * 2012-03-14 2013-09-19 Ruprecht-Karls-Universität Heidelberg Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2014078749A1 (en) 2012-11-15 2014-05-22 The Regents Of The University Of California Splice modulating oligonucleotides that inhibit cancer
EP2931893A1 (en) 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
CN103820454B (zh) * 2014-03-04 2016-03-30 上海金卫生物技术有限公司 CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA
SG11201608701QA (en) * 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2016138278A2 (en) * 2015-02-27 2016-09-01 Idera Pharmaceuticals, Inc. Compositions for inhibiting checkpoint gene expression and uses thereof
BR112017020750A2 (en) * 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
MX2017015239A (es) * 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology

Similar Documents

Publication Publication Date Title
JP7423015B2 (ja) キメラ2重鎖核酸
US11260134B2 (en) Double-stranded nucleic acid complex having overhang
ES2562658T3 (es) Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne
US10538763B2 (en) Compounds and methods for modulation of DUX4
US11433089B2 (en) Blood-brain barrier permeable heteroduplex nucleic acid
EP2961841B1 (en) Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
CA3172168A1 (en) Synthesis of modified oligonucleotides with increased stability
JP2023158214A (ja) Hif2αの遺伝子発現を阻害する組成物及び方法
JP2022528487A5 (cg-RX-API-DMAC7.html)
CN115397436B (zh) 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法
IL262199A (en) Oligonucleotides for the treatment of eye disease
JP2020530981A (ja) T細胞の機能を調節するためのアンチセンスオリゴヌクレオチド
WO2016149020A1 (en) Rna interference agents
JP2018519831A5 (cg-RX-API-DMAC7.html)
KR20180104692A (ko) Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료
US20250388901A1 (en) Advanced rna targeting (arnatar)
WO2016149659A2 (en) Antisense-induced exon exclusion in myostatin
WO2016149323A1 (en) Immunomodulatory spherical nucleic acids
EP3532617A1 (en) Antisense oligonucleotides
WO2021070959A1 (ja) 修飾ヘテロ核酸
US20220162599A1 (en) Methods and compositions for modulating splicing of alternative introns
US20150329857A1 (en) Rna interference to activate stem cells
Eritja et al. Challenges and opportunities for oligonucleotide-based therapeutics by antisense and RNA interference mechanisms
CN121889505A (zh) 抑制actriib表达的寡核苷酸分子及其用途
EP4720299A1 (en) Tgfb2-irf5 therapeutics for cancer